APRE
Aprea Therapeutics, Inc.0.9110
-0.0141-1.52%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.75MP/E (TTM)
-Basic EPS (TTM)
-2.12Dividend Yield
0%Recent Filings
8-K
8-K
8-K
APR-1051 partial responses
Aprea Therapeutics posted Q4 2025 net loss of $2.5M, down from $2.9M, with cash at $14.6M funding into Q1 2027 after $8.7M private placements. APR-1051 scored two unconfirmed partial responses in PPP2R1A-mutated endometrial cancers at 150mg and 220mg doses; well-tolerated. Dose escalation rolls on. ATRN-119 paused monotherapy for combos.
10-K
FY2025 results
Aprea Therapeutics posted FY2025 net loss of $12.6M, improved from $13.0M in FY2024, with R&D expenses dropping to $7.0M from $9.4M as ATRN-119 monotherapy enrollment paused after RP2D determination while exploring combinations. Q4 saw APR-1051 advance to cohort 8 at 220mg with two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer, signaling early proof-of-concept. Cash burned to $14.6M by year-end, sufficient into Q1 2027 post-January raise. No revenue; grant income fell to $0.3M. Clinical holds risk trial momentum.
8-K
Second uPR in APR-1051 trial
Aprea Therapeutics reported a second unconfirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, with 50% tumor shrinkage and 87% CA-125 drop in an advanced endometrial cancer patient at the 220 mg dose. Both responses occurred in PPP2R1A-mutated tumors; the patient saw only Grade 1 adverse events. Responses need confirmation. Further updates due Q2 2026.
ALLR
Allarity Therapeutics, Inc.
1.07+0.01
APLM
Apollomics Inc.
17.02+0.92
APLT
Applied Therapeutics, Inc.
0.12+0.00
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
GNPX
Genprex, Inc.
2.43-0.15
LPTX
Leap Therapeutics, Inc.
2.05+1.61
MNPR
Monopar Therapeutics Inc.
71.47-3.65
PRLD
Prelude Therapeutics Incorporat
1.99+0.05
RPTX
Repare Therapeutics Inc.
2.23+0.03